Frederic Guerard - Jun 24, 2025 Form 4 Insider Report for CalciMedica, Inc. (CALC)

Role
Director
Signature
/s/ John Dunn, Attorney-in-Fact
Stock symbol
CALC
Transactions as of
Jun 24, 2025
Transactions value $
$0
Form type
4
Date filed
6/26/2025, 06:25 PM
Previous filing
Jun 11, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Guerard Frederic Director C/O CALCIMEDICA, INC., 505 COAST S. BLVD, #202, LA JOLLA /s/ John Dunn, Attorney-in-Fact 2025-06-26 0001825009

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CALC Director Stock Option (Right to Buy) Award $0 +10K $0.00 10K Jun 24, 2025 Common Stock 10K $1.53 Direct F1, F2
transaction CALC Director Stock Option (Right to Buy) Award $0 +5K $0.00 5K Jun 24, 2025 Common Stock 5K $1.53 Direct F1, F3
transaction CALC Director Stock Option (Right to Buy) Award $0 +15K $0.00 15K Jun 24, 2025 Common Stock 15K $1.53 Direct F1, F4
transaction CALC Director Stock Option (Right to Buy) Award $0 +10K $0.00 10K Jun 24, 2025 Common Stock 10K $1.65 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option grant was approved by the Board of Directors of CalciMedica, Inc. (the "Company") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the "Amended 2023 EIP") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025.
F2 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following March 26, 2025.
F3 Immediately exercisable.
F4 1/9th of the shares subject to the option vest in equal monthly installments over a one year period following April 1, 2025.
F5 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following June 24, 2025, provided that the shares will in any case be fully vested on the date of Company's 2026 annual meeting of stockholders